More Videos
- Getting To The Heart Of The Merck-Abbott Embargo Break
- Merck: Both Sides Now
- A Public Hearing That Isn't Public
- Fighting The Flu Vaccine Critics
- Merck’s Mega-Monday Morning
- What Not To Wear At Sanofi-Pasteur
- Merck: Live Long And Prosper
- Lights, Camera, Lipitor!
- Biopharma's Bustin' Out All Over
- Friday At The Fat Fight
SPECIAL REPORT
MOST SHARED
- Stocks Overvalued, Recession Will Return: Meredith Whitney
- Has Twitter's Finest Hours (Seconds) Come and Gone?
- Fed Likely to Keep Rates Low Despite Dollar's Fall: Bernanke
- U.S. May Wind Up Green With Envy
- Bernanke Offers Something For Everyone
- BofA Ex-Counsel: I Was 'Stunned' When I Got Fired
- Vineyard Serves Up Sustainable Wine
- U.S. Cities With The Most Underwater Mortgages
- Warren Buffett's Berkshire Hathaway Almost Doubles Wal-Mart Holdings During Summer
- Stanford Receiver to Release Funds Of Frozen Acounts
- Meredith Whitney: Turns Bearish
- 3 Stock Plays on Rising College Costs
- Warren Buffett's Berkshire Hathaway Almost Doubles Wal-Mart Holdings During Summer
- Nov. 16: Unusual Volume Leaders
- Getting To The Heart Of The Merck-Abbott Embargo Break
- What MGM's Sale Could Say About Value of Content
- My Ratings on Lowe's & Home Depot: Analyst
- S&P Stocks Trading at New 52-Week Highs
- Snoop Dogg Talks Biz
- Buffett's Berkshire Hathaway Boosts Wal-Mart Stake
- What's Kept Stock Rally Going? Fear, Not Confidence
- Fed to Keep Rates Low Despite Dollar's Fall: Bernanke
- Millions Could Have to Repay Part of Obama's Tax Credit
- Hollywood Turns to Porn as Unemployment Rises
- Slideshow: US Cities With Most Underwater Mortgages
- Solar Energy Emerges From a Dark Period
- Gold Is in a 'Bubble' And Will Keep Going Higher: Gartman
- Stanford Receiver to Release Funds Of Frozen Acounts
PHARMA'S MARKET VIDEO
RSS FEED
Pharma's Market
Text Size 
I've blogged many times about the embargoes imposed by scientific groups and medical journals. If a media outlet breaks one -- something I have not done -- they risk losing the "privilege" of receiving the info ahead of time. And there's been a recent example of a prominent doctor who spoke too soon and has been barred for a while from publishing and reviewing studies in a peer-reviewed journal. Well, now at least one organization may take the enforcement a step further.
Reuters broke the story that three research analysts -- one at Merrill Lynch, another at Natexis Bleichroeder and the third at JPMorgan -- issued reports earlier this week with embargoed data from the upcoming American Academy of Neurology conference.
Two of the research notes to clients were about an experimental Alzheimer's drug from Baxter [BAX
Loading...
()
]. And the other note focused on the MS drug Tysabri from BIIB [BIIB
Loading...
()
] and ELN [ELN
Loading...
()
].
Reuters says the JPM and Natexis reports were retracted or recalled and that Merrill declined to comment.
But a spokesperson for the AAN says the recall or retraction may not be sufficient and that the organization could possibly try to take some kind of legal action. Here's their statement:
“The American Academy of Neurology is disappointed that representatives of financial organizations have deliberately violated the Academy’s embargo policy. The violation has been referred to the Academy’s General Counsel who is currently exploring all options available to the Academy.”
The embargo issue keeps cropping up for the organizations and journals that are trying to protect their "scientific integrity" and potentially headline-making content while servicing the companies that often sponsor the research (and the conferences) and in which Wall Street has a vested interest.
It will once again be put to the test over the next couple of months when the most widely-followed conference by doctors, scientists, investors, reporters and analysts--the American Society of Clinical Oncology annual meeting--employs a new policy this year with some of its data to try to satisfy everyone.
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes